drugset / Trial / NCT01425632

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01425632

Phase 3 Completed 490 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis, and to investigate the dose response, safety, and plasma concentrations of TAU-284.

Timeline

Start
2011-08
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bepotastine Small molecule 10 mg
Subject Bepotastine Small molecule 20 mg